Background: The purpose of this study is to analyze the pooled results of multimodality treatment of locally advanced rectal cancer (LARC) in four major treatment centers with particular expertise in intraoperative radiotherapy (IORT).
introduction
The introduction and acceptance in surgical practice that the rectum should be removed within its enveloping mesorectal fascia have led to a decline in local recurrence (LR) rate in rectal cancer treatment [1] . A direct inverse relation between tumor distance to the mesorectal fascia and LR has been established; a distance of £1 mm is associated with a high LR rate [2, 3] . In this study, locally advanced rectal cancer (LARC) is defined by the high probability of circumferential margin involvement. The patients described have a threatened or involved mesorectal fascia (T3+ or T4 tumors) assessed by computed tomography or magnetic resonance (MR) imaging.
Preoperative radiotherapy (RT) has been used to facilitate surgical resection by downsizing LARC. Still, in many patients, areas at risk will remain, but normal tissue tolerance limits the dose of RT [4] . Chemotherapy has been added to the RT to overcome dose limitations and to enhance the tumoricidal effect of the neoadjuvant treatment [5] .
Another approach to overcome dose limitations is to apply intraoperative radiotherapy (IORT) boost to a specific area [6] . IORT allows the deliverance of a radiation boost, biologically comparable to an additional 30-40 Gy fractionated irradiation, to a well-defined volume under direct vision, with a possibility to shield or remove dose-sensitive structures. However, the IORT equipment is expensive and the logistics are complex.
original article
Furthermore, nonmetastasized LARC is not very common. Therefore, in Europe, a few centers implemented this type of combination therapy. In this paper, the long-term results of IORT multimodality treatment have been pooled and analyzed in four major IORT expert centers. Concerning adjuvant treatment, adjuvant chemotherapy (aCT) has come to widespread use in colon cancer treatment [7, 8] . However, during the observed period, there was no consensus among clinicians whether the use of aCT should be standard in LARC. The four studied centers dealt differently with the implementation of aCT, creating the opportunity to analyze the effect in a large cohort of patients. Especially as aCT in LARC patients is being accepted gradually in Europe, this study is one of the few occasions to analyze the effect of adding aCT to the multimodality treatment of LARC.
patients and methods patients Four major referral centers for LARC have been involved in IORT since the early nineties of the last century. The centers are the University Hospital Gregorio Marañó n, Madrid, the Catholic University of the Sacred Heart Rome, the University of Heidelberg and the Catharina Hospital, Eindhoven. The patients of the four centers have been pooled from the beginning of their IORT program until 2005. Patients with preoperative distant metastases (DM) were excluded from this study, leaving 605 patients for analyses. Median follow-up time for surviving patients was 56 months (range 10-164 months).
treatment
In Table 1 , the similarities and differences between the centers are shown. Over the years, the adjuvant and neoadjuvant treatment schemes have changed within each center. However, the basic treatment principle (RT, followed by resection and an IORT boost) remained constant. In all the centers, IORT was delivered as an electron boost during open surgery. The IORT dose and energy was comparable in all centers and was typically in range from 10 to 12.5 Gy, the energies ranged from 8 to 12 MEV and the most used diameter of the beveled applicator was 6 cm. The RT dose was typically in the range of 45 to 50.4 Gy in fractions from 1.8 to 2.0 Gy. The use of additional chemotherapy to preoperative radiotherapy (CRT) was not introduced at the same time at all centers. The chemotherapy in neoadjuvant and adjuvant setting was based on 5-fluorouracil schemes in all centers, of which the details have been described before [6, [9] [10] [11] . That all four centers have gradually accepted the use of CRT and aCT for their patients leaves sufficient control patients who did not have aCT.
statistical analysis
Statistical analysis was carried out using SPSS package (SPSS 16.0 for Windows; SPSS Inc, Chicago, IL). t-tests and chi-square tests were used to compare individual variables. LR rate, DM rate, cancer-specific survival (CSS) and overall survival (OS) were estimated using the Kaplan-Meier method. CSS was defined as the time between rectal cancer surgery and death caused by rectal cancer. Differences were assessed using the log-rank test. P values were two-sided and considered statistically significant at a value of £0.05. For determination of risk factors, first univariate analyses were carried out by analyzing the effect of the covariates in a univariate Cox regression, stratifying for treatment center. Then, covariates with trendsignificant effects (P value < 0.10) were selected for multivariate analysis, stratifying for treatment centers, using stepwise Cox proportional hazards regression modeling. Both forward and backward stepwise regression was used and a two-sided P value of <0.05 was considered significant. A baseline prognostic model for prognostic factors was created by using the b-values per variable after multivariate analysis. Consequently, for each prognostic index group, a survival curve was made using the Kaplan-Meier method.
results

effect of treatment modalities
For preoperatively staged T3+ carcinomas, 42% received CRT; for T4 cancers, this was 78% (P < 0.001). Any downstaging was achieved in 31% of the patients treated with RT and in 59% of the patients with CRT (P < 0.001). Complete remission occurred in 4% and 11% of patients treated with RT and CRT, respectively (P < 0.001). Radicality of the resection was not dependent on whether downstaging had occurred or not (P = 0.18). Lymph nodes (LNs) were positive in 41% of the patients after RT and in 30% after CRT (P = 0.008). In patients treated with CRT, the distance of the lower tumor border to the anus was not different from the patients treated with RT, but the type of surgery turned to more sphincter-saving procedures after CRT (P < 0.001). The administration of aCT was independent of margin positivity (P = 0.07) and tumor-nodemetastasis stage (P = 0.13).
local and distant recurrence
Overall, 61 patients developed LR (12.0% 5-year LR rate). After uni-and multivariate analyses (Tables 2 and 3 ), the risk factors associated with LR were no downstaging, LN positivity, margin involvement and no aCT. In Figure 1 , LR rates after multivariate analysis are shown. In the patients who received aCT, LR rate was 5.5% and 12.0% in the patients who did not (P = 0.026). Analyzing subgroups, when any downstaging had been achieved by preoperative treatment, LR rate after aCT was 5.6%, not significantly different from the 8.1% LR rate without aCT (P = 0.087). aCT seemed to improve LR rates from 21.6% to 12.3% in patients with tumors in which no downstaging had occurred after preoperative treatment (P = 0.031). Irradical surgery resulted in a LR rate of 45.1% in 5 years, while this was 9.5% after radical surgery (P < 0.001). In patients with positive margins, LR rate was 23.8% in patients who had aCT and 57.4% in patients who had not (P = 0.030). 5-Year DM rate was 29.2%. Male gender, preoperatively staged T4 disease, no downstaging, LN positivity and margin involvement were associated with a higher risk for DM (Tables 2  and 3 ). aCT did not influence DM rate, as shown in Figure 2. survival OS was 67.1% after 5 years. Risk factors for death were age older than 70 years, male gender, no downstaging, LN positivity, margin involvement and no aCT (Tables 2 and 3 ). Postoperative death within 3 months after surgery was 5.3% in patients aged 70 years or older, compared with 1.8% in patients younger than 70 years (P = 0.020). Excluding the patients who died within 3 months from the analysis still resulted in lower OS in the elderly patients. However, this was mainly due to other causes of death than cancer, as CSS was not significantly different in elderly, compared with younger patients (P = 0.897). CSS was 73.5% after 5 years; significant risk factors after multivariate analysis were male gender, LN positivity and margin involvement. Covariates with trend-significant effects (P value < 0.10) in univariate analysis entered in the multivariate analysis, stratifying for treatment centers. HR, hazard ratio; CI, confidence interval; n.a., variables which were not trend significant in univariate analysis. In Figure 3 , OS according to prognostic index categories are shown. The differences between the groups were significant (P < 0.001).
discussion
In this study, the long-term results of individual patient data of four major centers practicing IORT-containing multimodality treatment in LARC were pooled. The advantage of a pooled analysis is that sufficient numbers of patients with adequate follow-up can be studied, to reach the power necessary for conclusions. However, the risk is that due to different selection mechanisms, an uncontrolled bias may be introduced. An incomplete or inconsistent dataset constitutes a potential threat to a meaningful analysis. The four hospitals in this paper that have pooled their results are considered reference centers for the treatment of LARC. The use of multimodality treatment has been studied in a prospective manner over the years. Therefore, the centers share the basic treatment principles and have complete and concise data. But still, the results have to be interpreted with caution.
The overall results of the pooled analysis demonstrate that the basic treatment principle was successful, with a LR rate of 12.0%, a DM rate of 29.2% and an OS of 67.1%. This treatment principle consisted of RT, followed by surgical resection, which was extended if necessary to obtain free surgical margins, and consequently the application of IORT. This basic scheme has been modulated by the addition of CRT and administration of aCT to a part of the patients.
In uni-and multivariate analyses, three independent factors influenced oncological results in terms of LR, DM and OS majorly, namely downstaging, LN status and margin involvement. This study showed that downstaging was more often achieved after CRT than after RT, justifying the switch to CRT in the four treatment centers. The fact that only specialized treatment centers were analyzed may be the explanation that downstaging did not significantly improve radicality of the resections in this cohort of patients. Preoperative LN status could not be assessed adequately when no MR images were available, so this variable was not taken into consideration. However, pathological LN status seems to be affected by CRT, as LN positivity was significantly lower after CRT, even when these were more clinical T4 tumors. Further, as margin involvement has been repeatedly confirmed as a major factor influencing treatment results [3, 12, 13] , adequate multidisciplinary treatment planning is essential to prevent irradical surgery. The risk model allows determination of prognosis in individual patients with LARC. As risk factors accumulate, death occurs in up to 80% of the patients after 5 years, so more aggressive adjuvant treatment modalities should be considered seriously in patients with a high prognostic index.
The role of adjuvant aCT in rectal cancer is still subject of debate and research in several European countries. It is known that adherence to aCT is generally poor. However, this study is strongly in favor of the use of aCT. LR rate seems to be improved significantly, with a reduction in LR of 6.5% after aCT. This would mean a number needed to treat of 100/6.5 = 16 patients, to prevent one case of LR. A striking finding was that aCT even seemed to reduce the development of LR when surgical margins were positive or when no downstaging had occurred after preoperative treatment. These are, however, post hoc calculations, making it difficult to draw conclusions from these findings. Although we did not find an improvement in CSS after aCT, gradually evidence is increasing that aCT can improve survival [8, 14, 15] and LR rates [16] , at least in a selected group of rectal cancer patients. This turns the adagio upside down that aCT does not penetrate into fibrotic tissue in the operation field. This phenomenon may cast a new light on the multimodality treatment with IORT, followed by aCT. One could contemplate that high-dose local RT sensitized the operation field for subsequent aCT.
Surprisingly, the development of DM was not prevented by aCT. LARC in this study is biologically characterized by local growth without the development of early DM. Maybe these tumors represent a genotype relatively insensitive to the usual aCT used for prevention of DM. Further molecular research is needed to elucidate this finding. Another explanation may be the late administration of aCT. From the time of diagnosis to the actual delivery of aCT, it takes >5 months, but this is even longer when complications occur. Unfortunately, it is difficult to study the quantitative effect of IORT. But fact is that the 5-year LR rate of 12.0% is very low in this high-risk group of patients. Further, 55% of the patients with positive surgical margins did not develop LR, suggesting that these residual tumor cells were sterilized. Interesting is that the area of IORT application differs between IORT centers; some attack the area most considered at risk [6, 14] and some always irradiate the presacral space [17, 18] . In a previous study [19] , it was suggested that IORT to the area at risk results in less infield LR than presacral IORT. It was hypothesized that presacral recurrences mainly occur from spill from other areas and that these postoperatively migrating tumor cells can thus not be sterilized by a boost on the presacral space.
Concluding, the four studied centers have improved their survival and LR rates by the use of their basic treatment approach in LARC. The first step in this approach is to administer CRT in order to downstage the tumor and facilitate surgical resection. aCT could lower the chance of LR in the vast majority of patients. It is tempting to assume that a highdose local RT plays a role in the increased potential of aCT to prevent LRs. 
